Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Natalizumab - Biogen/Perrigo

Drug Profile

Natalizumab - Biogen/Perrigo

Alternative Names: AN 10022; AN 100226; Antegren; Anti-alpha4 integrin monoclonal antibody - Biogen/Perrigo; BG-00002; BG-0002; BG-0002-E; Tysabri

Latest Information Update: 24 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Elan Corporation
  • Developer Biogen; Biogen Idec; Elan Corporation; Perrigo
  • Class Anti-inflammatories; Antiepileptic drugs; Antineoplastics; Antirheumatics; Immunotherapies; Monoclonal antibodies; Vascular disorder therapies
  • Mechanism of Action Integrin alpha4beta1 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Multiple sclerosis
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Crohn's disease; Multiple sclerosis
  • Phase II Graft-versus-host disease
  • Discontinued Epilepsy; Multiple myeloma; Rheumatoid arthritis; Stroke

Most Recent Events

  • 11 Oct 2023 Adverse events data from the phase III NOVA trial in Multiple sclerosis were presented at the 9th Triennial joint meeting of Americas Committee for Treatment and Research in Multiple Sclerosis and the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS-ACTRIMS)
  • 24 Jul 2023 Biogen completes the phase-IIIb NOVA trial in Multiple Sclerosis in USA, Australia, Belgium, Canada, France, Germany, Israel, Italy, Netherlands, Spain and the UK (SC; IV) (NCT03689972)
  • 22 Apr 2023 Efficacy data from clinical TOUCH programme in Multiple sclerosis presented at the 75th Annual Meeting of the American Academy of Neurology 2023 (AAN-2023)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top